Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer.

Future oncology (London, England) - 1 Jan 2024

Princic Nicole, Marrett Elizabeth, Kwong Winghan Jacqueline, McMorrow Donna, Schwartz Hana, Subramanian Janakiraman

Abstract excerpt

Aim: Compare healthcare costs for patients with epidermal growth factor receptor mutated (EGFRm) metastatic non-small-cell lung cancer (mNSCLC) with and without progression and estimate costs of progression.Materials & methods: Retrospective claims analysis (2015-2020) from adults with EGFRm mNSCLC initiating EGFR tyrosine kinase inhibitors. Adjusted costs for 12 months were compared (with vs without progression)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to ErbB Receptors

Share to Health Care Costs

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39011928
DOI: 10.1080/14796694.2024.2370186
PMCID: PMC11486167

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer.PMID 39011928Read ↗

Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study.Semantic proximity Read ↗

Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors.Semantic proximity Read ↗

Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type.Semantic proximity Read ↗

Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review.Semantic proximity Read ↗

Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Does pathologic type shape the hospitalization costs of advanced non- small cell lung cancer patients? A multicenter real-world data studySemantic proximity Read ↗

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.Semantic proximity Read ↗

Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI.Semantic proximity Read ↗

Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.